RESEARCH ON RESEARCH INTEGRITY
RELEASE DATE: May 30, 2003
RFA: NS-04-001
Office of Research Integrity (ORI)
(http://ori.hhs.gov/)
National Institute of Neurological Disorders and Stroke (NINDS)
(http://www.ninds.nih.gov/)
National Institute of Nursing Research (NINR)
(http://www.ninr.nih.gov/)
National Institute on Drug Abuse (NIDA)
(http://www.nida.nih.gov/)
Agency for Healthcare Research and Quality (AHRQ)
(http://www.ahrq.gov)
CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBER(S): 93.279 (NIDA), 93.361 (NINR),
93.853 (NINDS), 93.226 (AHRQ)
LETTER OF INTENT RECEIPT DATE: October 14, 2003
APPLICATION RECEIPT DATE: November 14, 2003
THIS RFA CONTAINS THE FOLLOWING INFORMATION
o Purpose of this RFA
o Research Objectives
o Mechanism(s) of Support
o Funds Available
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Special Requirements
o Where to Send Inquiries
o Letter of Intent
o Submitting an Application
o Peer Review Process
o Review Criteria
o Receipt and Review Schedule
o Award Criteria
o Required Federal Citations:
PURPOSE OF THIS RFA
The Office of Research Integrity (ORI, DHHS), the National Institute of
Neurological Disorders and Stroke (NINDS, NIH), the National Institute
of Nursing Research (NINR, NIH), the National Institute on Drug Abuse
(NIDA, NIH), and the Agency for Healthcare Research and Quality (AHRQ,
DHHS) invite applications to support research on research integrity.
The purpose of the proposed grant program is to foster empirical
research on societal, organizational, group, and individual factors
that affect, both positively and negatively, integrity in research.
Proposals must have clear relevance to biomedical, behavioral and
health services research. Applicants are strongly encouraged to take
into consideration problems or issues that are relevant to the missions
of DHHS, NIH, or specific NIH institutes and programs.
For the purposes of this RFA, "research" is interpreted broadly to
include societal, organizational, group, and individual aspects of the
enterprise. "Integrity" is understood as "the use of honest and
verifiable methods in proposing, performing, and evaluating research in
reporting research results with particular attention to adherence to
rules, regulations, guidelines, and commonly accepted professional
codes or norms."
RESEARCH OBJECTIVES
Background
Over the last 10-15 years, researchers have devoted increased effort to
the empirical study of integrity in research with the encouragement of
new journals, focused initiatives, such as the Peer Review Congresses,
and the NIH/ORI Research Program on Research Integrity (established in
2000). The growing body of research on research integrity has enhanced
understandings of integrity in research and some of the factors that
influence the way researchers behave. However, information is still
lacking on the impact of specific research behaviors and of efforts to
promote integrity in research on the research record and the overall
practice of research.
This RFA seeks applications for empirical research that adds to
understandings of the ways in which research integrity and efforts to
promote responsible conduct in research directly or indirectly impact
the research record, research institutions, and/or the benefits derived
from biomedical and behavioral research. Four specific areas of
interest are outlined below.
Areas of Interest
Integrity and the reliability of the research record. While it is
generally understood that some inappropriate research behaviors, such
as deliberate misconduct, can adversely impact the research record, our
understanding of the relationships among different aspects of integrity
and the overall reliability of the research record are far from
complete. Proposals are welcomed that will:
o define and assess the prevalence of research practices that depart
from rules, regulations, guidelines, and commonly accepted norms for
responsible conduct in research;
o assess the importance of specific questionable practices on the
research record e.g. poor data management, sloppy research, unmanaged
conflicts of interest, the use of inappropriate methods, improper
authorship, and partial or inaccurate reporting of research methods and
findings; and/or
o develop and test ways to assess the reliability of the research
record, including not only final publications but grant applications
and professional statements.
Integrity and research relationships. Responsible research practice
has become increasingly complicated by the growth of complex and new
research relationships. Proposals are welcomed that will:
o investigate how collaborative research is organized and its impact on
research integrity, with particular interest in clinical research;
o define and assess the influence of international collaboration on
responsible research practices and the research record;
o investigate and assess the impact of changing financial
relationships, such as SBIR grants, licensing agreements, and other
financial arrangements, on research integrity and/or
o study the challenges for responsible conduct presented in high-
profile collaborative and international research, e.g. AIDS and other
major disease/health programs.
Fostering a commitment to responsible conduct in research. Since 1990,
research institutions have devoted considerable attention to ways of
fostering responsible conduct in research. To help evaluate what has
been accomplished and develop plans for future efforts, proposals are
welcomed that will:
o study factors that influence research behavior;
o develop and assess the effectiveness of different ways (courses, Web
programs, videos, mentoring, and so on) to promote responsible conduct
in research; and/or
o provide a comprehensive assessment (content and cost) of specific
efforts to foster responsible conduct in research.
Influence of the research environment. In a recent report, an
Institute of Medicine Committee recommended that "Federal agencies and
foundations should fund research designed to assess the relationship
between various elements of the research environment and integrity in
research, including similarities and differences across disciplines and
institutions" (Integrity in Scientific Research, 2002). Following this
recommendation, proposals are welcomed that will:
o clarify and assess the importance of environmental elements that
influence integrity in research;
o provide a comprehensive assessment (cost and elements) of specific
institutional efforts to promote integrity in research;
o assess the impact of changes in significant environmental elements,
such as funding patterns, major research priorities, and technology
transfer, on research integrity;
o define and assess ways to study the impact of policies, procedures,
practices, and other approaches to promote responsible research at the
institutional, departmental, or laboratory level; and/or
o develop and test assessment tools for institutions and laboratories
to measure specific aspects of responsible research and research
integrity.
Relevant research perspectives and disciplines include, but are not
limited to: anthropology, applied philosophy, business, economics,
education, information studies, law, organizational studies, health
services, political science, psychology, sociology, and survey and
evaluation research, plus the physical, biomedical, and clinical
sciences, including nursing. The NINR is particularly interested in
research done by nurses on these areas of interest. The AHRQ is
particularly interested in research done by health services researchers
on these areas of interest.
MECHANISM OF SUPPORT
This RFA will use NIH R01 award mechanism. As an applicant you will be
solely responsible for planning, directing, and executing the proposed
project. This RFA is a one-time solicitation. Future unsolicited,
competing-continuation applications based on this project will compete
with all investigator-initiated applications and will be reviewed
according to the customary peer review procedures. The anticipated
award date is July 2004.
This RFA uses just-in-time concepts. It also uses the modular
budgeting format. (See
http://grants.nih.gov/grants/funding/modular/modular.htm)
Specifically, if you are submitting an application with direct costs in
each year of $250,000 or less, use the modular format.
FUNDS AVAILABLE
The ORI intends to commit approximately $1,400,000 in FY 2004 to fund
new grants in response to this RFA. NINDS, NINR, NIDA, and AHRQ may
provide additional funding for projects relevant to their research
programs. Awards pursuant to this RFA are contingent upon the
availability of funds and the receipt of a sufficient number of
meritorious applications.
An applicant may request a project period of up to 3 years and a budget
for direct costs of up to $250,000 per year. Because the nature and
scope of the proposed research will vary from application to
application, it is anticipated that the size and duration of each award
will vary.
Applicants developing new research areas or assembling new,
interdisciplinary project teams should consider proposing limited,
short-term projects to establish the methods for and validity of the
work they propose to do (e.g. $75,000-100,000/ year for one or two
years). Larger, longer-term applications should be limited to major
data collection efforts that involve multiple institutions, phased
surveys, detailed direct or on site analysis, or other major research
work that cannot be accomplished in smaller studies.
In addition to new applications, amended applications for unfunded
projects previously submitted to NIH in response to preceding RFAs from
ORI will be accepted. Competitive continuations of existing projects
are not eligible under this RFA.
ELIGIBLE INSTITUTIONS
You may submit an application if your institution has any of the
following characteristics:
o For-profit or non-profit organizations
o Public or private institutions, such as universities, colleges,
hospitals, and laboratories
o Units of State and local governments
o Eligible agencies of the Federal government
o Domestic or foreign (if there are compelling reasons for carrying out
the research in a foreign country)
INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS
Any individual with the skills, knowledge, and resources necessary to
carry out the proposed research is invited to work with their
institution to develop an application for support. Individuals from
underrepresented racial and ethnic groups as well as individuals with
disabilities are always encouraged to apply for NIH programs.
SPECIAL REQUIREMENTS
Successful applicants will be asked to participate in future ORI-
sponsored conferences on research on research integrity to report
progress, discuss problems, and share information related to the
conduct of their grants. It is recommended that costs associated with
attendance of the principal investigator at one meeting per year in
Bethesda, Maryland, be included as part of the budget proposal.
WHERE TO SEND INQUIRIES
We encourage inquiries concerning this RFA and welcome the opportunity
to answer questions from potential applicants. Inquiries may fall into
three areas: scientific/research, peer review, and financial or grants
management issues:
o Direct your questions about scientific/research issues to:
Mary D. Scheetz, Ph.D.
Office of Research Integrity
1101 Wootton Parkway, Suite 750
Rockville, MD 20852
(301) 443-5302
Email: MScheetz@osophs.dhhs.gov
Mary Ellen Michel, Ph.D.
NINDS/NIH
Neuroscience Center, Room 2209, MSC 9525
6001 Executive Boulevard
Bethesda, MD 20892-9525
(301) 496-1447
Email: mm108w@nih.gov
Martha Hare, Ph.D.
National Institute of Nursing Research
6701 Democracy Boulevard
One Democracy Plaza
Bethesda, MD 20892-4870
(301) 451-3874
Email: mh421d@nih.gov
Noble Jones, M.Ed.
Center for AIDS and Other Medical Consequences
NSC, Suite 5198, MSC 9593
National Institute on Drug Abuse
Bethesda, MD 20892-9593
(301) 402-0807
nj11q@nih.gov
Sally Flanzer, Ph.D.
Agency for Health Care Research and Quality
Office of Research Review, Education, and Policy
540 Gaither Road, Room 2-2042
Rockville, Maryland 20850
(301) 427-1538
Email: sflanzer@ahrq.gov
o Direct your questions about peer review issues to:
Philip F. Wiethorn, Ph.D.
Scientific Review Branch
National Institute of Neurological Disorders and Stroke
6001 Executive Boulevard, Suite 3208
Rockville, Maryland 208512
Telephone: (301) 496-9223
Email: pw73q@nih.gov
o Direct your questions about financial or grants management matters
to:
Ms. Sheila Simmons
Grants Management Branch
National Institute of Neurological Disorders and Stroke
Neuroscience Center, Room 3290
6001 Executive Boulevard
Bethesda, Maryland 20892-9231
Telephone: (301) 496-9231
Email: ss433y@nih.gov
LETTER OF INTENT
Prospective applicants are asked to submit a letter of intent that
includes the following information:
o Descriptive title of the proposed research
o Name, address, and telephone number of the Principal Investigator
o Names of other key personnel
o Participating institutions
o Number and title of this RFA
Although a letter of intent is not required, is not binding, and does
not enter into the review of a subsequent application, the information
that it contains allows IC staff to estimate the potential review
workload and plan the review.
The letter of intent is to be sent by the date listed at the beginning
of this document. The letter of intent should be sent to:
Mary Ellen Michel, Ph.D.
NINDS/NIH
Neuroscience Center, Room 2209, MSC 9525
6001 Executive Boulevard
Bethesda, MD 20892-9525
Rockville, MD 20852 (for courier service)
FAX: (301) 480-1080
Email: mm108w@nih.gov
SUBMITTING AN APPLICATION
Applications must be prepared using the PHS 398 research grant
application instructions and forms (rev. 5/2001). The PHS 398 is
available at http://grants.nih.gov/grants/funding/phs398/phs398.html in
an interactive format. For further assistance contact GrantsInfo,
Telephone (301) 710-0267, Email: GrantsInfo@nih.gov.
SPECIFIC INSTRUCTIONS FOR MODULAR GRANT APPLICATIONS: Applications
requesting up to $250,000 per year in direct costs must be submitted in
a modular grant format. The modular grant format simplifies the
preparation of the budget in these applications by limiting the level
of budgetary detail. Applicants request direct costs in $25,000
modules. Section C of the research grant application instructions for
the PHS 398 (rev. 5/2001) at
http://grants.nih.gov/grants/funding/phs398/phs398.html includes step-
by-step guidance for preparing modular grants. Additional information
on modular grants is available at
http://grants.nih.gov/grants/funding/modular/modular.htm.
USING THE RFA LABEL: The RFA label available in the PHS 398 (rev.
5/2001) application form must be affixed to the bottom of the face page
of the application. Type the RFA number on the label. Failure to use
this label could result in delayed processing of the application such
that it may not reach the review committee in time for review. In
addition, the RFA title and number must be typed on line 2 of the face
page of the application form and the YES box must be marked. The RFA
label is also available at:
http://grants.nih.gov/grants/funding/phs398/label-bk.pdf.
SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten
original of the application, including the Checklist, and three signed,
photocopies, in one package to:
Center For Scientific Review
National Institutes Of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)
At the time of submission, two additional copies of the application
must be sent to:
Dr. Alan Willard
Chief, Scientific Review Branch
National Institute of Neurological Disorders and Stroke
6001 Executive Boulevard, Suite 3208
Rockville, Maryland 20852 (for express/courier service)
APPLICATION PROCESSING: Applications must be received on or before the
application receipt date listed in the heading of this RFA. If an
application is received after that date, it will be returned to the
applicant without review.
Although there is no immediate acknowledgement of the receipt of an
application, applicants are generally notified of the review and
funding assignment within 8 weeks.
The Center for Scientific Review (CSR) will not accept any application
in response to this RFA that is essentially the same as one currently
pending initial review, unless the applicant withdraws the pending
application. However, when a previously unfunded application,
originally submitted as an investigator-initiated application, is to be
submitted in response to an RFA, it is to be prepared as a NEW
application. That is the application for the RFA must not include an
Introduction describing the changes and improvements made, and the text
must not be marked to indicate the changes. While the investigator may
still benefit from the previous review, the RFA application is not to
state explicitly how.
PEER REVIEW PROCESS
Upon receipt, applications will be reviewed for completeness by the CSR
and responsiveness by the NINDS and ORI. Incomplete and/or non-
responsive applications will be returned to the applicant without
further consideration.
Applications that are complete and responsive to the RFA will be
evaluated for scientific and technical merit by an appropriate peer
review group convened by the NINDS in accordance with the review
criteria stated below. As part of the initial merit review, all
applications will:
o Receive a written critique
o Undergo a process in which only those applications deemed to have the
highest scientific merit, generally the top half of the applications
under review, will be discussed and assigned a priority score
o Receive a second level review by the appropriate national advisory
council or board.
REVIEW CRITERIA
The purpose of the proposed grant program is to foster empirical
research on research behaviors that adversely affect the research
record and on the effect of efforts to change these behaviors through
education and/or institutional reform. Studies must have relevance to
biomedical and behavioral research and be directly relevant to the
missions of DHHS and NIH.
In the written comments, reviewers will be asked to discuss the
following aspects of your application in order to judge the likelihood
that the proposed research will have a substantial impact on the
pursuit of these goals:
o Significance
o Approach
o Innovation
o Investigator
o Environment
The scientific review group will address and consider each of these
criteria in assigning the application's overall score, weighting them
as appropriate for each application. The application does not need to
be strong in all categories to be judged likely to have major
scientific impact and thus deserve a high priority score. For example,
an investigator may propose to carry out important work that by its
nature is not innovative but is essential to move a field forward.
(1) SIGNIFICANCE: Does this study address an important problem? Will
it make a significant contribution to understandings of research
behaviors that adversely affect the research record and on the effect
of efforts to change these behaviors through education and/or
institutional reform?
(2) METHOD: Are the conceptual framework, design, methods, and analyses
adequately developed, well-integrated, and appropriate to the aims of
the project? Will the study result in significant generalizable
empirical information? Has the applicant conducted a thorough review of
the existing literature? Does the applicant acknowledge potential
problem areas and consider alternative tactics?
(3) INNOVATION: Are the aims original and innovative? Does the project
challenge existing paradigms or develop new methodologies or
technologies? Does the project employ novel concepts, approaches or
methods?
(4) INVESTIGATORS: Is the principal investigator appropriately trained
and well suited to carry out this work? Is the work proposed
appropriate to the experience level of the principal investigator and
other researchers (if any)? Are appropriate or necessary collaborations
in place? Does the research team include appropriate expertise for the
scope of the project?
(5) ENVIRONMENT: Does the scientific environment in which the work will
be done contribute to the probability of success? Do the proposed
investigations take advantage of unique features of the intellectual
environment or employ useful collaborative arrangements? Is there
evidence of institutional support?
ADDITIONAL REVIEW CRITERIA: In addition to the above criteria, the
following items will be considered in the determination of scientific
merit and the priority score:
PROTECTION OF HUMAN SUBJECTS FROM RESEARCH RISK: The involvement of
human subjects and protections from research risk relating to their
participation in the proposed research will be assessed. (See criteria
included in the section on Federal Citations, below).
INCLUSION OF WOMEN, MINORITIES AND CHILDREN IN RESEARCH: The adequacy
of plans to include subjects from both genders, all racial and ethnic
groups (and subgroups), and children as appropriate for the scientific
goals of the research. Plans for the recruitment and retention of
subjects will also be evaluated. (See Inclusion Criteria in the
sections on Federal Citations, below).
CARE AND USE OF VERTEBRATE ANIMALS IN RESEARCH: If vertebrate animals
are to be used in the project, the five items described under Section f
of the PHS 398 research grant application instructions (rev. 5/2001)
will be assessed.
ADDITIONAL CONSIDERATIONS
DATA SHARING: The adequacy of the proposed plan to share data
BUDGET: The reasonableness of the proposed budget and the requested
period of support in relation to the proposed research.
RECEIPT AND REVIEW SCHEDULE
Letter of Intent Receipt Date: October 14, 2003
Application Receipt Date: November 14, 2003
Peer Review Date: March 2004
Council Review: May 2004
Earliest Anticipated Start Date: July 2004
AWARD CRITERIA
Award criteria that will be used to make award decisions include:
o Scientific merit (as determined by peer review)
o Availability of funds
o Programmatic priorities.
REQUIRED FEDERAL CITATIONS
HUMAN SUBJECTS PROTECTION: Federal regulations (45CFR46) require that
applications and proposals involving human subjects must be evaluated
with reference to the risks to the subjects, the adequacy of protection
against these risks, the potential benefits of the research to the
subjects and others, and the importance of the knowledge gained or to
be gained.
http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm
MONITORING PLAN AND DATA AND SAFETY MONITORING BOARD: Research
components involving Phase I and II clinical trials must include
provisions for assessment of patient eligibility and status, rigorous
data management, quality assurance, and auditing procedures. In
addition, it is NIH policy that all clinical trials require data and
safety monitoring, with the method and degree of monitoring being
commensurate with the risks (NIH Policy for Data and Safety Monitoring,
NIH Guide for Grants and Contracts, June 12, 1998:
http://grants.nih.gov/grants/guide/notice-files/not98-084.html).
INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH: It is the policy
of the NIH that women and members of minority groups and their sub-
populations must be included in all NIH-supported clinical research
projects unless a clear and compelling justification is provided
indicating that inclusion is inappropriate with respect to the health of
the subjects or the purpose of the research. This policy results from
the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43).
All investigators proposing clinical research should read the "NIH
Guidelines for Inclusion of Women and Minorities as Subjects in
Clinical Research - Amended, October, 2001," published in the NIH Guide
for Grants and Contracts on October 9, 2001
(http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html);
a complete copy of the updated Guidelines are available at http://
grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm.
The amended policy incorporates: the use of an NIH definition of
clinical research; updated racial and ethnic categories in
compliance with the new OMB standards; clarification of language
governing NIH-defined Phase III clinical trials consistent with the new
PHS Form 398; and updated roles and responsibilities of NIH staff and
the extramural community. The policy continues to require for all NIH-
defined Phase III clinical trials that: a) all applications or
proposals and/or protocols must provide a description of plans to
conduct analyses, as appropriate, to address differences by sex/gender
and/or racial/ethnic groups, including subgroups if applicable; and b)
investigators must report annual accrual and progress in conducting
analyses, as appropriate, by sex/gender and/or racial/ethnic group
differences.
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN
SUBJECTS: The NIH maintains a policy that children (i.e., individuals
under the age of 21) must be included in all human subjects research,
conducted or supported by the NIH, unless there are scientific and
ethical reasons not to include them. This policy applies to all initial
(Type 1) applications submitted for receipt dates after October 1, 1998.
All investigators proposing research involving human subjects should
read the "NIH Policy and Guidelines" on the inclusion of children as
participants in research involving human subjects that is available at
http://grants.nih.gov/grants/funding/children/children.htm
REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS: NIH
policy requires education on the protection of human subject
participants for all investigators submitting NIH proposals for
research involving human subjects. You will find this policy
announcement in the NIH Guide for Grants and Contracts Announcement,
dated June 5, 2000, at http://grants.nih.gov/grants/guide/notice-files/
NOT-OD-00-039.html.
HUMAN EMBRYONIC STEM CELLS (hESC): Criteria for federal funding of
research on hESCs can be found at
http://stemcells.nih.gov/index.asp and at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html.
Only research using hESC lines that are registered in the NIH Human
Embryonic Stem Cell Registry will be eligible for Federal funding (see
http://escr.nih.gov). It is the responsibility of the applicant to
provide the official NIH identifier(s)for the hESC line(s)to be used in
the proposed research. Applications that do not provide this
information will be returned without review.
PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT:
The Office of Management and Budget (OMB) Circular A-110 has been
revised to provide public access to research data through the Freedom of
Information Act (FOIA) under some circumstances. Data that are (1)
first produced in a project that is supported in whole or in part with
Federal funds and (2) cited publicly and officially by a Federal agency
in support of an action that has the force and effect of law (i.e., a
regulation) may be accessed through FOIA. It is important for
applicants to understand the basic scope of this amendment. NIH has
provided guidance at
http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this PA in a public
archive, which can provide protections for the data and manage the
distribution for an indefinite period of time. If so, the application
should include a description of the archiving plan in the study design
and include information about this in the budget justification section
of the application. In addition, applicants should think about how to
structure informed consent statements and other human subjects
procedures given the potential for wider use of data collected under
this award.
STANDARDS FOR PRIVACY OF INDIVIDUALLY IDENTIFIABLE HEALTH INFORMATION:
The Department of Health and Human Services (DHHS) issued final
modification to the "Standards for Privacy of Individually Identifiable
Health Information", the "Privacy Rule," on August 14, 2002. The
Privacy Rule is a federal regulation under the Health Insurance
Portability and Accountability Act (HIPAA) of 1996 that governs the
protection of individually identifiable health information, and is
administered and enforced by the DHHS Office for Civil Rights (OCR).
Those who must comply with the Privacy Rule (classified under the Rule
as "covered entities") must do so by April 14, 2003 (with the
exception of small health plans which have an extra year to comply).
Decisions about applicability and implementation of the Privacy Rule
reside with the researcher and his/her institution. The OCR website
(http://www.hhs.gov/ocr/) provides information on the Privacy Rule,
including a complete Regulation Text and a set of decision tools on "Am
I a covered entity?" Information on the impact of the HIPAA Privacy
Rule on NIH processes involving the review, funding, and progress
monitoring of grants, cooperative agreements, and research contracts
can be found at http://grants.nih.gov/grants/guide/notice-files/
NOT-OD-03-025.html.
URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and
proposals for NIH funding must be self-contained within specified page
limitations. Unless otherwise specified in an NIH solicitation, Internet
addresses (URLs) should not be used to provide information necessary to
the review because reviewers are under no obligation to view the
Internet sites. Furthermore, we caution reviewers that their anonymity
may be compromised when they directly access an Internet site.
HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to
achieving the health promotion and disease prevention objectives of
"Healthy People 2010," a PHS-led national activity for setting priority
areas. This RFA is related to one or more of the priority areas.
Potential applicants may obtain a copy of "Healthy People 2010" at
http://www.health.gov/healthypeople.
AUTHORITY AND REGULATIONS: This program is described in the Catalog of
Federal Domestic Assistance at http://www.cfda.gov/ and is not subject
to the intergovernmental review requirements of Executive Order 12372
or Health Systems Agency review. Awards are made under the
authorization of Sections 301 and 405 of the Public Health Service Act
as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR 52
and 45 CFR Parts 74 and 92. All awards are subject to the terms and
conditions, cost principles, and other considerations described in the
NIH Grants Policy Statement. The NIH Grants Policy Statement can be
found at http://grants.nih.gov/grants/policy/policy.htm.
The PHS strongly encourages all grant recipients to provide a smoke-
free workplace and discourage the use of all tobacco products. In
addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits
smoking in certain facilities (or in some cases, any portion of a
facility) in which regular or routine education, library, day care,
health care, or early childhood development services are provided to
children. This is consistent with the PHS mission to protect and
advance the physical and mental health of the American people.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
|
|
|
Department of Health and Human Services (HHS)
|
|
|
|
NIH... Turning Discovery Into Health®
|